Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: Larazotide evidence and protocol review
Also known as: AT-1001, Larazotide acetate
Larazotide (AT-1001) is a peptide zonulin antagonist that reduces pathological intestinal and endothelial permeability by modulating intercellular tight-junction competency via the zonulin pathway. A published systematic review covers larazotide's therapeutic use across celiac disease, type 1 diabetes, other autoimmune diseases, inflammatory bowel disease, Kawasaki disease, and respiratory conditions, reflecting its broadest clinical development to date in celiac disease as a non-dietary adjunct therapy.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Larazotide remains investigational. The 0.5 mg arm showed a symptom signal in Phase 2, but the later Phase 3 program was discontinued for lack of benefit.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.